# Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions

> **NCT05417893** · NA · WITHDRAWN · sponsor: **Meril Life Sciences Pvt. Ltd.**

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)

## Key facts

- **NCT ID:** NCT05417893
- **Lead sponsor:** Meril Life Sciences Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-15
- **Primary completion:** 2023-09-23
- **Final completion:** 2023-09-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Operational and feasibility constraints due to regulatory requirements
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05417893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05417893, "Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05417893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*